Summary & Overview
HCPCS S0013: Esketamine Nasal Spray, 1 mg
HCPCS Level II code S0013 designates esketamine nasal spray measured as 1 mg units. Esketamine is an NMDA receptor modulator used in certain treatment-resistant or acute psychiatric indications; accurate coding of the product and unit is essential for claims processing, pharmacy reimbursement, and tracking drug utilization nationally. This code matters because high-cost novel therapies administered in outpatient behavioral health settings can drive variation in payer coverage, prior authorization practices, and site-of-service billing.
Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what S0013 represents, payer coverage considerations, common billing modifiers and administrative details, and the clinical and service contexts in which the code is used. The publication summarizes benchmarks for utilization and payment where available, outlines policy and coverage trends affecting outpatient dispensing of esketamine nasal spray, and provides practical coding context for revenue cycle and clinical teams.
Data not available in the input is noted where applicable; the content focuses on national implications rather than state-specific policies.
Billing Code Overview
HCPCS Level II code S0013 represents esketamine, nasal spray, 1 mg as the billed pharmaceutical item. This HCPCS entry denotes the specific drug formulation and unit of measure for esketamine supplied as a nasal spray.
Service type: Drug administration / pharmacologic therapy
Typical site of service: Outpatient clinic or infusion center where nasal spray medications are dispensed or administered, including behavioral health clinics or specialized outpatient treatment settings.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 38-year-old adult with treatment-resistant major depressive disorder presents to an outpatient specialty clinic for supervised administration of intranasal esketamine. The patient has failed multiple oral antidepressant trials and meets clinical criteria for esketamine therapy under a risk evaluation and mitigation strategy (REMS) program. On arrival, nursing completes baseline vital signs, brief cognitive and dissociation scales, and confirms no recent benzodiazepine or opioid use. A prescriber (psychiatrist) documents the indication, reviews consent, and orders S0013 (esketamine, nasal spray, 1 mg) with the appropriate dose and monitoring plan.
The medication is prepared and administered in the clinic by a registered nurse or qualified clinician. The patient self-administers the prescribed number of sprays under direct supervision; the clinician documents lot numbers, number of milligrams delivered, and any partial doses (apply modifier as appropriate). The patient remains in the clinic for at least two hours for monitoring for sedation, dissociation, blood pressure changes, and respiratory status. Post-observation documentation includes vital signs, adverse effects, counseling provided, and plan for follow-up maintenance dosing or referral. Typical visit frequency is induction (twice weekly) followed by tapering to weekly or monthly maintenance per protocol.
Typical site of service: outpatient infusion/medication administration unit, psychiatric clinic, or ambulatory specialty center with REMS-compliant monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|